HDAC11 and metabolic dysfunction-associated steatotic liver disease: In summary, this study identifies HDAC11 as a potential therapeutic target in MASLD and reports the discovery of a highly selective HDAC11 inhibitor with favorable drug‐like properties for the treatment of MASLD.